Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVETRIC: Avelumab, Cetuximab, and mFOLFOXIRI in RAS Wild-type mCRC
NCT04513951Phase 2Completed
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Apr 2020
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in metastatic colorectal cancer (mCRC), sponsored by Gruppo Oncologico Nord Ovest. Started Apr 2020; status: completed.
02
Drugs
avelumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04513951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513951.